ZyVersa Therapeutics received a Letter of Reprimand from Nasdaq for not obtaining stockholder approval prior to a public offering and for repricing warrants, but no further action is required. They also filed a preliminary proxy statement for a special stockholders meeting to approve a reverse stock split to cure a bid price deficiency.